Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could avert this tragedy with decisive action.
Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable medicines and educating patients.
Novartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based pricing.
Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
Novartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
Harald Nusser, Head of Novartis Social Business, explains why educating young people is key to fighting chronic disease in South-East Asia.
Harald Nusser, Head of Novartis Social Business, talks about how the pharmaceutical industry can work with partners to overcome access issues in poor countries.
Intellectual Property drives innovation and protects lives. On World IP Day find out how?
David Reddy, CEO Medicines for Malaria Venture and Harald Nusser, Head of Novartis Social Business, explain how new partnerships fight emerging malaria resistance and help eliminate the disease for good.
Harald Nusser, Head of Novartis Social Business shares his insights following the latest National Malaria Control Program best practice sharing workshop in Dakar.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.